A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.


Updates from The Motley Fool

Latest updates on VIVUS from Fool.com.  The Fool has written over 400 articles on VIVUS.
Is VIVUS Inc. a Short Sell?

Shares of VIVUS Inc. have crashed by over 60% in the past year. Is the stock still a good short s...

Obesity Hype Meets Harsh Reality

Arena Pharmaceuticals' and VIVUS' obesity drugs have struggled out of the gate, which could be go...

3 Stocks to Get on Your Watchlist

An antiobesity laggard, one stock potentially ready to give short-sellers the figure-four leglock...

Why VIVUS, Inc. Shares Soared

VIVUS' first-quarter results crush Wall Street's estimates, but all is not what it appears to be.



Stock Performance

View Interactive VVUS Charts
Sponsored by

Key Data Points

Primary metrics and data points about VIVUS.
Current Price: $0.66
Prev Close: $0.67
Open: $0.67
Bid: $0.66
Ask: $0.68
Day's Range: $0.66 - $0.68
52wk Range: $0.61 - $1.47
Volume: 382,825
Avg Vol 797,820
Market Cap: $70M
P/E (ttm): 1.91
EPS (ttm): $0.35
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about VIVUS.
CAPS Rating 4 out of 5
 
345 Outperform
62 Underperform
CAPS All Stars
 
46 Outperform
17 Underperform

How do you think VIVUS will perform against the market?



You pick for VIVUS is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Leland F. Wilson, CEO

48% Approve

Based on 5 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for VIVUS.

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers